Ironwood Pharmaceuticals IRWD Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

Lexicon PharmaceuticalsLXRX

$9.4M+1,016%

Bausch Health CompaniesBHC

——

Neurocrine BiosciencesNBIX

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$106.5M+159%

Operating income$72.6M+349%

Net income$40.8M+209%

EPS (diluted)$0.24+204%

Balance sheet

See full

Cash & equivalents$220.5M+103%

Total debt$212.4M+1,323%

Total equity-$217.1M+35.0%

Total assets$434.6M+32.8%

Cash flow

See full

Operating cash flow$5.1M-74.3%

CapEx-—

Free cash flow$74.6M+390%

Valuation

See full

Market cap$632.12M+457%

Enterprise value$624M+3,024%

P/E6.2×—

P/S1.8×+1.4×

Profitability

See full

Gross margin99.2%—

Operating margin55.4%+38.7pp

Net margin28.3%+22.3pp

FCF margin24.7%-11.1pp

Returns & leverage

See full

Return on equity29.7%-138pp

Debt / equity0×-0.5×

Current ratio1.4×-1.9×

Where this comes from

Reported directly by Ironwood Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ironwood Pharmaceuticals's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ironwood Pharmaceuticals's increase (decrease) in accounts receivable?: Ironwood Pharmaceuticals (IRWD) reported increase (decrease) in accounts receivable of $59.1M in Q1 2026.
How has Ironwood Pharmaceuticals's increase (decrease) in accounts receivable changed year-over-year?: Ironwood Pharmaceuticals's increase (decrease) in accounts receivable increased by 240.3% year-over-year, from -$42.12M to $59.1M.